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Summary
 
The herpes simplex virus (HSV) immediate early protein ICP47 inhibits the transporter associ-
ated with antigen processing (TAP)-dependent peptide translocation. As a consequence, empty
major histocompatibility complex (MHC) class I molecules are retained in the endoplasmic
reticulum and recognition of HSV-infected cells by cytotoxic T lymphocytes is abolished. We
chemically synthesized full-length ICP47 (sICP47) and show that sICP47 inhibits TAP-depen-
dent peptide translocation in human cells. Its biological activity is indistinguishable from that of
recombinant ICP47 (rICP47). By using synthetic peptides, we mapped the core sequence of
ICP47 minimally required for TAP inhibition to residues 2–35. This segment is located within
the region of the molecule conserved between ICP47 from HSV-1 and HSV-2. Through ala-
nine scanning substitution we identified three segments within this region that are critical for
the ability to inhibit TAP function. The interaction of ICP47 with TAP is unlikely to mimic
precisely that of the transported peptides, as deduced from differential labeling of the TAP1 and
TAP2 subunits using sICP47 fragments with chemical cross-linkers.
 
T
 
he MHC-encoded transporter associated with antigen
processing (TAP)
 
1
 
 connects the cytosol with the lu-
men of the endoplasmic reticulum (ER) to allow loading of
MHC class I molecules with cytosolic peptides for presen-
tation to CTL (1–3). This MHC class I–restricted pathway
is critical for elimination of most virus infections. TAP, a key
component of this pathway, is blocked specifically by the
herpes simplex virus (HSV) protein ICP47, a blockade that
allows escape from eradication by CTL (4, 5). TAP is a
member of the ATP-binding cassette (ABC) family of trans-
porters, which includes the cystic fibrosis transmembrane con-
ductance regulator (CFTR) and the multidrug resistance
transporter (MDR) (6). To date, ICP47 is the only known
natural inhibitor of a member of the ABC transporter fam-
ily. A better understanding of the mode of interaction be-
tween ICP47 and TAP is relevant not only for learning
more about viral evasion strategies, but could also inspire
the design of inhibitors for other members of the ABC
transporter family.
ICP47 of HSV-1 is an 87–amino acid cytosolic polypep-
tide, 88 residues if the initiation methionine is included. It
binds to the TAP1–TAP2 heterodimer in human but not
in mouse cells and prevents transport of peptides through
blockade of the peptide binding site of TAP (7, 8). As a
consequence, MHC class I molecules fail to be loaded with
peptides. The resultant empty class I molecules are retained
in the ER and presentation of epitopes to CTL is abolished
in HSV-infected human cells (4, 5).
The affinity of the human TAP–ICP47 interaction has
been estimated to be around 50 nM (9, 10). The ability of
ICP47 to prevent photocross-linking of peptides to TAP in-
dicated that ICP47 prohibited peptide binding to TAP (9).
Furthermore, the kinetics of competition between peptide
and ICP47 for binding to TAP indicate that ICP47 and
peptide may compete for a single binding site (9, 10). While
 
1
 
Abbreviations used in this paper:
 
 ABC, ATP-binding cassette; CFTR, cystic
fibrosis transmembrane conductance regulator; EGF, epidermal growth
factor; ER, endoplasmic reticulum; FPLC, fast performance liquid chro-
matography; HSV, herpes simplex virus; MDR, multidrug resistance
transporter; SLO, strepolysin O; TAP, transporter associated with antigen
processing; Tpa, 4
 
9
 
-(Trifluoromethyl–diazirinyl)-phenylalanine.
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suggestive, these experiments cannot readily distinguish
between a conformational distortion of TAP caused by
ICP47, or a direct competition for the binding site.
Here, we have used chemical synthesis to make full-
length ICP47, as well as NH
 
2
 
- and COOH-terminally
truncated versions and alanine-substituted peptide ana-
logues. We show that the ability of ICP47 to inhibit TAP
lies within the NH
 
2
 
-terminal half of the molecule, which is
highly conserved between ICP47 from HSV-1 and HSV-2.
We present evidence that the mechanism of interaction of
ICP47 with the TAP heterodimer likely differs from that of
its peptide substrates.
 
Materials and Methods
 
Synthesis and Purification of ICP47 and Truncations.
 
The peptides
used in this study were synthesized on a multiple peptide synthe-
sizer (model 350; Advanced Chemtech, Louisville, KY) by Fmoc
Figure 1. Synthetic ICP47 has
identical biological activity to re-
combinant ICP47. (A) Elution
profile of synthetic ICP47 on a
Sephacryl 100 column (48 cm 3
1 cm) equilibrated with 150 mM
NaHCO3, 10 mM NaCl, pH
8.5. The elution profile of
sICP47 is shown along with the
calibration graph for molecular
weight standards (BSA 66,000,
OVA 44,000, carbonic anhy-
drase 30,000, RNAse 13,700 and
cytochrome C 12,300). Kav is
plotted against the logarithm of
the molecular weight. Kav 5 (Ve 2
Vo) / (Vt 2 Vo), where Ve repre-
sents the elution volume of the
sample, Vo the void volume, and
Vt the total volume. (B) The hu-
man lymphoblastoid cell line
Hom2 was permeabilized using
SLO and incubated with syn-
thetic or recombinant ICP47-1
at the concentrations indicated,
and with the 125I-labeled peptide
library for 10 min at 378C as de-
scribed in Materials and Meth-
ods. Results represent the
amount of radiolabeled, glycosy-
lated peptides recovered with
Con A–Sepharose. Synthetic
ICP47 (sICP47) (closed symbols)
inhibits TAP function with the
same efficacy as recombinant
ICP47 (rICP47) (open symbols).
(C) Hom2 cells were incubated
with the 125I-labeled peptide li-
brary for 10 min at 378C for the
times indicated and with 5 mM
recombinant or synthetic ICP47
either treated with trypsin for 30
min at 378C or not treated. Ra-
dioactivity associated with Con
A–Sepharose is counted. Trypsin
destroys the biological activity of
both synthetic and recombinant
ICP47. (D) Hom2 cells were in-
cubated with the 125I-labeled
peptide library for 10 min at
378C and with various concen-
trations of synthetic ICP47 un-
heated (open squares) or heated to
958C for 30 min and then slow-
cooled (open circles) or snap-
cooled (closed squares). Results in
A, B, and C are the mean of du-
plicates 6 SD. 
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chemistry or on an ABI (Applied Biosystems, Inc., Foster City,
CA) peptide synthesizer (model 430A) by Tboc chemistry and
purified by fast performance liquid chromatography (FPLC) on a
Sephacryl 100 column or by reverse-phase HPLC on a C18 col-
umn. Their composition was verified by amino acid analysis and
also by mass spectrometry for full-length ICP47. Quantitation was
carried out by amino acid analysis or optical density measurement.
4
 
9
 
-(Trifluoromethyl–diazirinyl)-phenylalanine (Tpa) (11) was cou-
pled to peptide 1–35 (1–35 Tpa) during synthesis by using its Fmoc
derivative.
 
Antibodies.
 
Anti-TAP antiserum was raised against the TAP1
COOH-terminal domain (12) and the anti-ICP47 antiserum against
a COOH-terminal peptide of ICP47 (7).
 
DNA Sequence of the ICP47 Gene from HSV-2.
 
A KpnI–
HindIII fragment (8,477 bp) of HSV-2 strain HG52 genomic
DNA was cloned into pUC19, and fragments obtained by sonica-
tion then subcloned into M13mp8 for sequence determination by
chain terminator methods. The sequence comprised adjoining parts
of the short unique and short repeat regions of the genome, in-
cluding the gene for ICP47 (US12), and will be submitted to the
EMBL Library as part of the whole genomic sequence of HSV-2
(Dolan, A., and D.J. McGeoch, unpublished observations).
 
Peptide Translocation Assay.
 
Peptide translocation was performed
esentially as described (7). In brief, cells were washed twice with
transport buffer (130 mM KCl, 10 mM NaCl, 1 mM CaCl
 
2
 
, 2
mM EGTA, 2 mM MgCl 
 
2
 
, 5 mM Hepes [pH 7.3] with KOH)
at 4
 
8
 
C and then permeabilized (10
 
7
 
 cells/ml) in transport buffer
containing 2 U/ml of streptolysin O (SLO) (bioMérieux, Marcy-
l’Etoile, France) for 10 min at 37
 
8
 
C. Permeabilization was as-
sessed by Trypan blue exclusion. Permeabilized cells (10
 
6
 
 cells/
sample in Eppendorf tubes) were incubated for 10 min at 37
 
8
 
C
with 10 
 
m
 
l of the radioiodinated peptide library (13) and 10 
 
m
 
l of
ATP generating system (50 
 
m
 
M ATP, 250 
 
m
 
M UTP, 2.5 mM
creatine phosphate, and 8 U creatine phosphokinase; Sigma Chem-
ical Co., St. Louis, MO) in a total volume of 100 
 
m
 
l at 37
 
8
 
C.
When indicated, synthetic ICP47 was added to the translocation
mixture in a volume of 10 
 
m
 
l. Peptide translocation was termi-
nated by adding 1 ml of ice-cold stop buffer (transport buffer plus
10 mM EDTA, 0.02% Na azide). Samples were centrifuged at
14,000 rpm, supernatant was removed, and 1 ml of ice-cold lysis
buffer (0.5% NP-40, 5 mM MgCl 
 
2
 
, 50 mM Tris–HCl [pH 7.5])
added. After 20 min, debris was removed by centrifugation at
14,000 rpm and the supernatant incubated with gentle agitation
for 1 h with 100 
 
m
 
l of Con A–Sepharose beads (Pharmacia, Upp-
sala, Sweden) at 4
 
8
 
C. Beads were washed three times with lysis
buffer and radioactivity quantitated by 
 
g
 
 counting.
 
Metabolic Labeling and Immunoprecipitation.
 
TK143 human fi-
broblasts (American Type Culture Collection, Rockville, MD)
and Ft1
 
1
 
 mouse embryonic fibroblasts (gift from L. van Kaer,
Howard Hughes Medical Institute, Vanderbilt University School
of Medicine, Nashville, TN) were infected with a recombinant
vaccinia virus expressing human TAP1
 
1
 
TAP2 (7) at a multiplic-
ity of infection of 10. 1 h after infection, medium was removed
and cells were labeled overnight with [
 
35
 
S]methionine/cysteine.
Cells were lysed in NP-40 lysis buffer (0.5% NP-40, 50 mM
Tris–HCl [pH 7.2], 5 mM MgCl
 
2
 
) and immunoprecipitations
were performed as described (14). Immune complexes were re-
covered on 
 
Staphylococcus aureus
 
 (Staph A) protein A and washed
four times with NET buffer (50 mM Tris–HCl [pH 7.4], 0.5%
NP-40, 150 mM NaCl, 5 mM EDTA) and analyzed by SDS-
PAGE on 10% or 12.5% gels.
 
Gel Electrophoresis.
 
SDS-PAGE and fluorography were per-
formed as described (15).
 
Peptide Iodination.
 
Peptides were iodinated by the chloramine
T method as described (16).
 
Cross-linking Assays.
 
TK143 cells infected with vaccinia virus
expressing human TAP1
 
1
 
2 in the conditions above described were
permeabilized with SLO as previously defined. 5 
 
3
 
 10
 
6
 
 cells were
resuspended in 200 
 
m
 
l of transport buffer and incubated with 100 
 
m
 
l
of 
 
125
 
I-labeled 1–35 Tpa or 1–35 polypeptide for 5 min on ice.
Cross-linking was induced by irradiation with long-wave UV
lamp (Fotoprep I, 120 V, 60 Hz; Fotodyne, New Berlin, WI) for
5 min on ice (17). Cells were then lysed and immunoprecipita-
tions were performed as described (14).
 
Results and Discussion
 
Biochemical and Functional Analysis of Synthetic ICP47-1.
 
An 87-amino acid polypeptide corresponding to ICP47
from HSV-1 (strain 17) without the initiating methionine
was synthesized on a solid phase support, the substitution
grade of which had been reduced to facilitate synthesis of
longer peptides. Nor-leucine was substituted for methio-
nine at positions 6 and 14 to avoid oxidation of these residues
during HF cleavage and workup of the synthetic product,
and lysine was substituted for arginine at the COOH terminus
Figure 2. Comparison of the ICP47 gene and protein sequences of
HSV-1 and HSV-2. (A) Alignment of coding sequences of the HSV-1
and HSV-2 (US12) genes. The ICP47 coding sequences of HSV-1 (top
line) and HSV-2 (bottom line) are shown from initiator ATG to translation
stop codon (TGA in each case), with identical aligned residues marked by
vertical lines. (B) Amino acid sequence comparison of ICP47 from HSV-2
and HSV-1. Regions of identical aligned sequence are boxed. 
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to facilitate future chemical modifications. Synthetic ICP47
(sICP47) eluted as a single major peak in gel chromatogra-
phy on a Sephacryl 100 matrix, showing a Gaussian distri-
bution with a Stokes radius corresponding to a molecular
weight of 19,000 for a globular protein (Fig. 1 
 
A
 
). We
conclude that sICP47 (molecular weight 9,598) does not
behave as a monomeric globular protein in aqueous solu-
tion, but rather like an unfolded polypeptide chain. Frac-
tions were pooled and analyzed by SDS-PAGE on 15%
gels. The results are consistent with a single major species
of the predicted molecular weight but with lower molecu-
lar weight contaminants clearly visible (data not shown).
Mass spectrometry revealed that the major product was of
predicted molecular weight, but again, the broad range of
masses observed indicated substantial heterogeneity, as ex-
pected for an 87-residue synthetic product.
The biological activity of sICP47 was compared with
that of recombinant ICP47 (rICP47) in a TAP-dependent
peptide transport assay in semi-intact human lymphoblas-
toid cells (Fig. 1 
 
B
 
). In this assay, the inhibitory activity of
sICP47 and rICP47 was indistinguishable. Both prepara-
tions inhibit human TAP, with 50% inhibition seen at ap-
proximately 0.2 
 
m
 
M. As with rICP47, the activity of sICP47
is destroyed by proteolysis with trypsin (Fig. 1 
 
C
 
) but not
by boiling sICP47 for 30 min (Fig. 1 
 
D
 
) (10). We exam-
ined the ability of sICP47 to inhibit TAP-dependent pep-
tide transport in mouse cells. As observed for rICP47 (9,
10), sICP47 was unable to block murine TAP at concen-
trations up to 10 
 
m
 
M (data not shown). We conclude that
the biological activity of sICP47 is indeed attributable to
the protein itself, and not to some other nonpeptide prod-
uct that might have persisted after gel filtration.
Solid-phase synthesis of ICP47 is thus a practical propo-
sition, and because the polypeptide is not exposed to pro-
teases during purification, yields a product that is more sta-
ble than rICP47. The purity of the resultant product is
adequate for quantitative functional studies. Additionally,
the ability to synthesize variants of the molecule rapidly
makes truncation and mutagenesis studies simple to per-
form.
 
Amino Acid Sequence of ICP47 from HSV-2 Reveals Ho-
mology Only in the NH
 
2
 
-terminal Region (Residues 1–54) of
the Molecule.
 
Both HSV-1 and HSV-2 inhibit TAP func-
tion and cause retention of MHC class I molecules in the 
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ER (5). The sequence of the 
 
US12
 
 gene (which encodes
ICP47) from HSV-2 (strain HG52) was determined. The
coding sequence for HSV-2 ICP47 was compared with its
HSV-1 counterpart (18, 19). The HSV-2 ICP47 gene con-
tains 86 codons. As shown in Fig. 2 
 
A
 
, the DNA sequences
are similar over most of their length, except that in or
around codon 59 in the HSV-1 sequence there is a 13-bp
deletion relative to the HSV-2 sequence; that is, there is an
apparent frameshift. Upstream of this location the encoded
amino acid sequences are closely similar (Fig. 2 
 
B), down-
stream the amino acid sequences are distinct, and the pre-
dicted translation termination sites do not coincide. Both
HSV-1 and HSV-2 DNA sequences were carefully checked
and no errors were found. Therefore, we consider that the
DNA sequence determination and our interpretation are
correct, and that a frameshift mutation (that occurred in ei-
ther HSV-1 or HSV-2) has been tolerated, presumably be-
cause the COOH-terminal region of ICP47 is not func-
tionally important. This view is consistent with studies on
the two proteins, including results in this paper.
Recombinant ICP47 from HSV-2 (rICP47-2) inhibited
human TAP with the same efficiency as did sICP47-1 (data
not shown). The preservation of biological activity be-
tween the two molecules, despite an apparent frameshift
mutation, suggests that it is the NH2-terminal region of the
molecule that interacts with TAP and that the COOH ter-
minus is not essential for activity.
Definition of the Core Region of ICP47 Responsible for TAP
Inhibition and Lack of Requirement for a Free a NH2 Group.
A 53-mer polypeptide (1–53) containing the NH2-terminal
region of ICP47 from HSV-1, highly conserved between
ICP47-1 and ICP47-2, was synthesized along with shorter
polypeptides lacking the NH2-terminal 4 or 9 residues. Ti-
tration of these products in a TAP-dependent assay showed
that ICP47-1–53 had activity identical to the full-length
molecule. However, removal of residues 1–4 profoundly
diminished activity (Fig. 3 A). Another synthesis was per-
formed in which NH2-terminal residues from the 1–53 poly-
peptide were progressively deleted. At 3.3-mM concentration,
only peptide 2–53 showed the same inhibitory activity as
full-length sICP47 (Fig. 3 B). Further peptides were made
with progressive deletions from the COOH terminus. Fig.
3 C shows that a peptide corresponding to residues 1–35
had identical inhibitory activity to the full-length molecule,
whereas shorter peptides were ineffective in blocking TAP.
Thus, we conclude that residues 2–35 contain the core
region responsible for TAP inhibition. Interestingly, the
longer peptide 1–40 did not inhibit effectively, perhaps due
to an unfavorable conformation adopted by this peptide in
solution, a possibility that has not yet been fully explored.
Next, an alanine scan was performed in which each non-
alanine residue in peptide 1–35 was replaced by an alanine.
The concentration of inhibitor peptides was chosen such
that for wild-type 1–35 polypeptide full inhibition had just
been reached (3.3 mM). Any loss of inhibitory activity
should now be discernible as an increase in peptide trans-
port. This experiment was performed not so much to de-
Figure 3. Synthetic peptides map the core region of ICP47-1 responsi-
ble for TAP inhibition to a segment between amino acids 2 and 35. Pep-
tide translocation was assayed in the human cell line Hmy2.C1R using
the 125I-radiolabeled peptide library as translocated substrate. Results are
means of duplicates 6 SD. (A) The activity of full-length synthetic ICP47
(open squares) was compared with that of the polypeptides containing resi-
dues 1-53 (open circles), 5-53 (closed squares), and 10-53 (closed circles) at the
concentrations indicated. (B) Inhibition of peptide translocation by
sICP47 is compared with that of synthetic 1–53 polypeptide with pro-
gressive truncations from the NH2-terminal residues at 3.3 mM concen-
tration. (C) The ability of sICP47 (open symbols) to block peptide transport
was compared with that of peptides with progressive truncations at its
COOH terminus (closed symbols) at the concentrations indicated. (D) An
alanine scan was performed by replacing each single residue in the
polypeptide 1–35 with alanine, except residues 3, 7, and 22 which are ala-
nine in the original ICP47 sequence. The ability of each of these alanine
analogues at a concentration of 3.3 mM to inhibit TAP function was
tested in a transport assay. Positions conserved between ICP47-1 and
ICP47-2 are in bold. Results represent percent peptide transport remain-
ing in the presence of ICP47 alanine analogues. 100% refers to transport
in the absence of inhibitors. The amino acid sequence of 1–35 polypep-
tide is shown. (E) Acetylation of sICP47 has no effect on its biological ac-
tivity. The ability of 1–53 polypeptide (open symbols) to inhibit TAP func-
tion was compared with that of its N-acetylated version (closed symbols) at
the concentrations indicated.1570 Use of Synthetic Peptides to Define the Active Site of ICP47
termine half-maximal inhibitory concentrations of each of
the substituted peptides, but to identify those regions of
ICP47-1–35 most likely to determine biological activity. Fig.
3 D shows the ability of these peptides to inhibit peptide
transport. Three regions (A, 8–12; B, 17–24; and C, 28–
31) appear important for the ability to inhibit TAP, with
segment 17–24 showing the least tolerance of alanine sub-
stitution at any residue, with the exception of position 20.
Finally, we note that transport of peptides by TAP can-
not be competed by NH2-terminal acetylation of the pep-
tide substrate (20). Because of the importance of the NH2-
terminal region of ICP47 to its ability to inhibit TAP, and
because ICP47 and transportable peptides compete for the
same binding site (9, 10), we tested whether N-acetylation
of ICP47 would inhibit its function. ICP47-1–53 was
N-acetylated on the resin before cleavage and deprotec-
tion. N-acetylation had no effect on the ability of ICP47-
1–53 to inhibit TAP (Fig. 3 E).
Short peptides used at a similar concentration to the
IC50 for ICP47 can act effectively as competitors for trans-
port of peptides by TAP (21). Therefore, the question arises
as to whether the truncations of ICP47 act to inhibit TAP
by the same mechanism as the full-length molecule, or sim-
ply serve as competitive inhibitors. We believe that the
mechanism is distinct from simple competitive inhibition
because (a) a series of peptides all terminating in residue 53,
and from 9 to 50 residues in length failed to inhibit (Fig. 3 B);
(b) results from other laboratories, using peptides of z30
amino acids long as competitive inhibitors of TAP, suggest
that pepides of this length generally bind poorly to the pep-
tide binding site of TAP (22); (c) the fact that N-acetylation
affects transport of peptide substrates (20), but not the abil-
ity of ICP47 to prevent transport; and (d) the inability of
ICP47 to inhibit mouse TAP (9, 10) all argue for distinct
modes of action.
The TAP Complex Coimmunoprecipitates with Synthetic
ICP47. The TAP1–TAP2 heterodimer coprecipitates
with ICP47 in cells infected with a recombinant adenovi-
rus expressing ICP47 (7) or stably transfected with ICP47
(8). To determine whether the TAP complex could be
coprecipitated with sICP47, sICP47 was introduced into
semi-intact mouse fibroblasts that had been infected with a
vaccinia vector expressing human TAP112 and then meta-
bolically labeled. Immunoprecipitations with the appropri-
ate antibodies revealed abundant synthesis of the TAP hetero-
dimer. The cells were permeabilized with SLO, incubated
with sICP47 for 10 min, and immunoprecipitated with an
antiserum against ICP47. TAP1 and TAP2 indeed copre-
cipitated with sICP47 (Fig. 4 A). More TAP was recovered
after a 10 min incubation at 378C than at 48C, presumably
reflecting a shorter equilibration time at the higher temper-
ature. Permeabilization and incubation with sICP47 of the
Figure 4. Synthetic ICP47
forms a complex with the TAP1
and TAP2 heterodimer. (A)
Mouse Ft11 fibroblasts were in-
fected with a recombinant vac-
cinia virus expressing human
TAP112 for 1 h and then la-
beled with [35S]methionine/cys-
teine overnight. SLO-permeabi-
lized cells were incubated for 10
min with synthetic ICP47 either
at 48C or 378C, lysed, and immu-
noprecipitated either with an anti-
TAP1 or with an anti-ICP47 an-
tiserum. Samples were analyzed
by 12.5% SDS-PAGE and fluo-
rography. The anti-ICP47 anti-
serum nonspecifically precipitates
a protein with a mobility identical
to that of the TAP1 subunit. (B)
Cross-linking with 1–35 Tpa re-
sults in labeling both TAP sub-
units, whereas only TAP1 subunit
is labeled with 1–35 polypeptide
labeled at Tyr 21. TK143 human
fibroblasts were infected with a
recombinant vaccinia virus ex-
pressing human TAP112. Cells were permeabilized with SLO and incubated for 5 min on ice either with 125I-radiolabeled 1–35 Tpa (lane 2) or with
125I-radiolabeled Tyr21 1–35 polypeptide (lane 3). Cross-linking was induced by exposure to long wave UV light for 5 min on ice. After lysis in 0.5%
NP-40 lysis buffer, samples were immunoprecipitated with an anti-TAP1 antiserum. As a control, TK143 cells infected with vaccinia virus expressing
TAP112 were metabolically labeled with [35S]methionine/cysteine and immunoprecipitated with the same anti-TAP1 antiserum (lane 1). Samples were
analyzed by 10% SDS-PAGE and fluorography. The position of migration of TAP1 and TAP2 was established based on the mobility of [35S]methionine/
cysteine–labeled samples. The increase in size observed for the cross-linked products is due to the covalent attachment of the 125I-labeled 1–35 fragment.
(C) Model of ICP47–TAP interaction. The NH2 terminus of ICP47 contacts both TAP subunits, whereas residue 21 (Y21) binds only to TAP1 subunit.
Likely, the COOH-terminal half of ICP47 does not interact with TAP.1571 Galocha et al.
semi-intact cells in PBS rather than the normal K1-based
intracellular transport buffer did not affect the coprecipita-
tion of TAP (data not shown).
Photocross-linking of ICP47-1–35 to TAP. To determine
whether the 1–35 polypeptide has the same ability as the
full-length sICP47 to interact with the TAP complex, a
cross-linkable 1–35-mer polypeptide was synthesized by
coupling the UV photoactivable phenylalanine analogue
Tpa to its NH2 terminus (1–35 Tpa). The ability to assign
the length of the active core of ICP47 to residues 1–35
makes the synthesis of the photoactivable analogue feasible.
This analogue also blocks TAP function, although less effi-
ciently than the unmodified 1–35 polypeptide (data not
shown). Although peptide substrates containing Tpa are
translocated normally by TAP (17), it is likely, given the
importance of the NH2-terminal region of ICP47 to its
function, that Tpa modification renders the molecule less
effective in blocking TAP.
Permeabilized human TK143 fibroblasts infected with a
recombinant vaccinia virus expressing human TAP112
were incubated with 125I-labeled 1–35 Tpa. Both TAP1
and TAP2 subunits were photolabeled with 1–35 Tpa cross-
linkable polypeptide with similar efficacy (Fig. 4 B).
Small polypeptides labeled with 125I at Tyr residues can
often be cross-linked to its receptor. While the chemistry
underlying this reaction is not known, it is a highly effec-
tive way of cross-linking epidermal growth factor (EGF) to
its receptor (23). We explored a similar strategy for 125I-Tyr21
labeled 1–35 polypeptide. We observed that only TAP1
crosslinks with this 125I-labeled Tyr21 1–35 polypeptide
(Fig. 4 B).
ICP47 inhibits TAP function by binding to a site in TAP
that includes both subunits and overlaps the peptide bind-
ing domain (9, 10). Because the NH2 terminus of ICP47
interacts with both TAP1 and TAP2 as deduced from cross-
linking with 1–35 Tpa, we suggest that ICP47 must con-
tact spatially close cytosolic domains in both subunits to al-
low residue Y21 in ICP47, where 125I-labeled moiety is
attached, to interact with TAP1 subunit (Fig. 4 C). Resi-
due 21 and adjoining residues (17–24) are particularly in-
tolerant of alanine substitution (see Fig. 3 D), emphasizing
the involvement of this region of ICP47 in binding and in-
hibition of TAP function.
The results presented here show that (a) residues 2–35
contain the core region responsible for TAP inhibition and
that (b) within this sequence, subregions are rather intoler-
ant of amino acid substitutions, suggesting that local con-
formation or specific local interactions may be necessary for
TAP inhibition. Thus, the distal frameshift between ICP47
coding sequences of ICP47 from HSV-1 and HSV-2 is tol-
erated, presumably because the COOH-terminal one-third
of the molecule is not functionally important. Of interest is
the fact that the sequence most highly conserved between
ICP47-1 and ICP47-2, between residues 33 and 47, lies
largely outside the region we have mapped as essential for
blockade of TAP. We assume that this region has been
conserved because it is important perhaps for the stability of
ICP47 inside the cell. Alternatively, this region may inter-
act with TAP outside the peptide binding area and account
for the prolonged association between TAP and ICP47
(10). As our assay involves the near simultaneous addition
of ICP47 and reporter peptide, we would not have de-
tected an alteration in the stability of the ICP47–TAP in-
teraction. However, we do note that the interaction of
peptide substrate with TAP has two distinct phases: binding
occurs regardless of the presence of ATP. Binding of ATP
to TAP then results in either transport of peptide or its
rapid dissociation from TAP (24). ICP47 is not transported
and avoids this ATP-induced dissociation (9, 10). We sug-
gest that interactions with TAP outside the peptide binding
site may be important for this stability. Mapping these sites
should facilitate the design of better inhibitors for TAP and
might perhaps be useful for identification or design of in-
hibitors of other members of the ABC transporter family.
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